Skip to main content
Midas Edge

AEON Biopharma, Inc.

For the period ended Jun 30, 2025. Filed Aug 12, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 12, 2025

AEON$0.18-1.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Deficit

(in thousands, except share data) (Unaudited)

​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · Additional · ​ · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · Paid-in · ​ · Subscription · ​ · Accumulated · ​ · Stockholders'
​ · ​ · Shares · ​ · Amount · ​ · Capital · ​ · Receivables · ​ · Deficit · ​ · Deficit
Balance as of January 1, 2025555,511​$4​$403,024​$—​$(431,597)​$(28,569)
Net income—​—​—​—​2,453​2,453
Issuance of shares and reclassification of liability related to cashless warrant exercises10,869,856​5​6,864​—​—​6,869
Issuance of shares related to at-the-market offering, net112,503​—​84​—​—​84
Stock-based compensation expense​—​—​3,311​—​—​3,311
Balance as of June 30, 202511,537,870​$9​$413,283​$—​$(429,144)​$(15,852)
​​​​​​​​​​​​​​​​​​
Balance as of January 1, 2024516,404​$4​$381,264​$(60,710)​$(473,602)​$(153,044)
Net income​—​—​—​—​46,094​​46,094
Termination of Forward Purchase Agreements​—​—​—​60,710​—​​60,710
Issuance of shares and reclassification of liability related to cashless warrant exercises​27,310​—​14,979​—​—​​14,979
Stock-based compensation expense​—​—​3,314​—​—​​3,314
Balance as of June 30, 2024543,714​$4​$399,557​$—​$(427,508)​$(27,947)
​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · Additional · ​ · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · Paid-in · ​ · Subscription · ​ · ​ · Accumulated · ​ · Stockholders'
​ · ​ · Shares · ​ · Amount · ​ · Capital · ​ · Receivables · ​ · Deficit · ​ · Deficit
Balance as of April 1, 202510,538,615​$9​$411,170​$—​$(422,502)​$(11,323)
Net loss—​$—​$—​$—​$(6,642)​(6,642)
Issuance of shares and reclassification of liability related to cashless warrant exercises​886,752​$—​$446​$—​$—​​446
Issuance of shares related to at-the-market offering, net​112,503​$—​$84​$—​$—​​84
Stock-based compensation expense​—​$—​$1,583​$—​$—​​1,583
Balance as of June 30, 202511,537,870​$9​$413,283​$—​$(429,144)​$(15,852)
​​​​​​​​​​​​​​​​​​
Balance as of April 1, 2024529,778​$4​$393,235​$—​$(591,620)​$(198,381)
Net income—​—​—​—​164,112​164,112
Issuance of shares related to cashless warrant exercises​13,936​​—​​4,629​​—​​—​​4,629
Stock-based compensation expense​—​​—​​1,693​​—​​—​​1,693
Balance as of June 30, 2024543,714​$4​$399,557​$—​$(427,508)​$(27,947)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.